<DOC>
	<DOC>NCT02570412</DOC>
	<brief_summary>Compassionate use of aldoxorubicin in sarcoma patients who have failed prior chemotherapy.</brief_summary>
	<brief_title>Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy</brief_title>
	<detailed_description>This is a compassionate use protocol allowing sarcoma patients that have relapsed after prior therapies and are not eligible for other protocols involving the evaluation of aldoxorubicin to receive aldoxorubicin.</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Metastatic or unrectable sarcoma that has either relapsed or was refractory to at leat 1 prior chemotherapy or immunotherapy regimen and for which no standard approved therapy exists Must not be eligible for another CytRxsponsored clinical trial Able to provide complete medical records for review by the CytRx Medical Monitor Able to receive treatment at a site that is participating or has participated in another CytRxsponsored aldoxorubicin trial Capable of providing informed consent and complying with trial procedures ECOG performance status 02 Measurable or evaluable tumor lesions according to RECIST 1.1 criteria Women must not be able to become pregnant (eg postmenopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be nonlactating Chemotherapy, palliative surgery and/or radiation treatment less than 30 days prior to screening for nontarget lesion Exposure to any investigational agent within 30 days of screening Central nervous system metastases that are symptomatic Laboratory values: Screening serum creatinine &gt;1.5×ULN, ALT &gt;3×ULN, or &gt;5×ULN if liver metastases are present, total bilirubin &gt;3×ULN, ANC &lt;1,500/mm3, platelet concentration &lt;100,000/mm3, hematocrit level &lt;25% for females or &lt;27% for males, coagulation tests (PT, PTT, INR) &gt;1.5×ULN Anion gap &gt; 16 meq/L or arterial or venous blood pH &lt; 7.30. Clinically evident congestive heart failure &gt; class II of the New York Heart Association (NYHA) guidelines Current serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V Baseline QTc &gt;470 msec and/or previous history of QT prolongation while taking other medications. Concomitant use of medications associated with a high incidence of QT prolongation is not allowed History or signs of active coronary artery disease with or without angina pectoris. Serious myocardial dysfunction defined scintigraphically (eg MUGA, myocardial scintigram) or ultrasound determined absolute LVEF &lt;45% of predicted History of HIV infection Active, clinically signifiant serious infection requiring treatment with antibiotics, antivirals or antifungals Major surgery within 3 weeks prior to enrollment Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>